Results round-up: S&N weak; HOLX, TFX, WMGI
This article was originally published in Clinica
Women’s health firm Hologic beat analyst expectations in its second fiscal quarter and raised its guidance as new CEO Stephen MacMillan continues to make his mark on the company. Jefferies analyst Raj Denhoy noted the new chief has already carried out “significant cost cutting.” He also “gave more details around his strategy, which centers around investing for organic growth, no major asset sales but instead smaller divestitures, debt service, and lower tax rate.”
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.